(Medical University of South Carolina) Charleston-based InDepth Pharmaceuticals has executed an option agreement with the Medical University of South Carolina Foundation for Research Development to evaluate and potentially commercialize a diagnostic tool to predict kidney transplant success in patients with focal segmental glomerulosclerosis (FSGS). The tool will identify those with recurrent FSGS, in whom transplanted kidneys are almost certain to fail, and possibly spare these patients the burden of a kidney transplant while preventing loss of valuable kidneys.

Original source: https://www.eurekalert.org/pub_releases/2020-01/muos-ipm011420.php